Evan David Seigerman
Stock Analyst at BMO Capital
(3.38)
# 1,000
Out of 5,090 analysts
54
Total ratings
51.06%
Success rate
4.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $725 → $850 | $718.36 | +18.33% | 9 | Dec 4, 2025 | |
| AMGN Amgen | Maintains: Outperform | $335 → $372 | $329.89 | +12.76% | 5 | Dec 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $46 | $47.86 | -3.89% | 8 | Nov 25, 2025 | |
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $10.61 | +3.68% | 5 | Nov 3, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $226.08 | +6.16% | 8 | Sep 12, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $20.28 | +28.21% | 2 | Jun 12, 2025 | |
| MRUS Merus | Maintains: Outperform | $96 → $110 | $96.14 | +14.42% | 1 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $27.44 | +2.04% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $12.79 | -21.81% | 1 | May 5, 2025 | |
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $99.72 | -3.73% | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $112 | $93.29 | +20.06% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $34.56 | +189.35% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $26.03 | +38.30% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $5.33 | -43.71% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $1,010.31 | -60.80% | 1 | Sep 6, 2022 |
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725 → $850
Current: $718.36
Upside: +18.33%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335 → $372
Current: $329.89
Upside: +12.76%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50 → $46
Current: $47.86
Upside: -3.89%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $10.61
Upside: +3.68%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $226.08
Upside: +6.16%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $20.28
Upside: +28.21%
Merus
May 23, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $96.14
Upside: +14.42%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $27.44
Upside: +2.04%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $12.79
Upside: -21.81%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $99.72
Upside: -3.73%
Nov 5, 2024
Maintains: Outperform
Price Target: $70 → $112
Current: $93.29
Upside: +20.06%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $34.56
Upside: +189.35%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $26.03
Upside: +38.30%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.33
Upside: -43.71%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $1,010.31
Upside: -60.80%